Prolia (Denosumab) Cost in South Dakota 2026

What Does Prolia (Denosumab) Actually Cost in South Dakota?

Brand-name Prolia carries an Amgen wholesale acquisition cost of approximately $1,500 per 60 mg prefilled syringe in 2026. South Dakota retail pharmacies reflect that same figure for cash-paying patients, making the annual out-of-pocket burden around $3,000 for the standard twice-yearly regimen. That price has not dropped meaningfully since 2024 because no FDA-approved biosimilar denosumab product had reached widespread South Dakota formularies as of mid-2025, though the FDA approved the first denosumab biosimilar (Jubbonti and Wyost, Samsung Bioepis) in 2024.

The $1,500 figure is the starting point, not what most patients pay. Insurance contracts, manufacturer assistance programs, and compounding pathways can each reduce that number substantially, sometimes to zero. Understanding which pathway applies to your specific situation requires checking your plan's formulary tier, your household income, and whether a 503A pharmacy near you (or accessible by mail) is dispensing compounded denosumab.

South Dakota has no state-level drug pricing assistance program specifically for Prolia. Patients must rely on federal or manufacturer-level programs, making it worth spending 20 minutes confirming eligibility before the first injection is ordered.

Denosumab's Clinical Basis: Why Physicians Prescribe It

Denosumab is a fully human monoclonal antibody that binds and inhibits RANK ligand (RANKL), a protein required for osteoclast formation, function, and survival. By blocking RANKL, denosumab reduces bone resorption and increases bone mineral density (BMD) at the spine, hip, and forearm. The FDA approved it in June 2010 for postmenopausal women with osteoporosis at high fracture risk, and subsequently for additional indications including bone loss in men receiving androgen deprivation therapy and glucocorticoid-induced osteoporosis. [1]

The phase 3 FREEDOM trial (N=7,868) published in the New England Journal of Medicine in 2009 remains the bedrock evidence. Denosumab 60 mg every six months reduced the risk of new vertebral fractures by 68% (relative risk 0.32 to 95% CI 0.26, 0.41, P<0.001) compared with placebo over 36 months. Hip fracture risk fell by 40% (hazard ratio 0.60 to 95% CI 0.37, 0.97, P=0.04) and nonvertebral fracture risk dropped by 20% (hazard ratio 0.80 to 95% CI 0.67, 0.95, P=0.01). [2]

"Denosumab significantly reduced the risk of vertebral, nonvertebral, and hip fractures in women with postmenopausal osteoporosis," the FREEDOM investigators wrote in their NEJM publication. [2]

Those efficacy figures help explain why the drug's list price has remained high: for patients at genuine fracture risk, the clinical value justifies the cost from a payer perspective, even if it does not make cash-pay access easy.

South Dakota Medicaid and Denosumab: What Patients Need to Know

South Dakota Medicaid does not currently cover Prolia (denosumab) for the osteoporosis indication. This is a common point of confusion because Medicare Part B does cover Prolia as a physician-administered injectable, and many patients conflate the two programs.

Why the distinction matters. South Dakota Medicaid (administered through the state's Department of Social Services) uses a preferred drug list that excludes denosumab for standard osteoporosis. Patients on Medicaid who need bone-protective therapy are typically directed toward oral bisphosphonates such as alendronate, which costs under $10 per month as a generic.

If a South Dakota Medicaid enrollee has a documented contraindication to bisphosphonates, the prescribing clinician may submit a prior authorization (PA) request citing clinical necessity. PA approval is not guaranteed and is evaluated on a case-by-case basis. The South Dakota Medicaid preferred drug list is updated periodically; patients and providers should confirm current status at the South Dakota Department of Social Services website before assuming coverage.

Medicare Part B is a separate federal program. Because Prolia is administered by a healthcare provider as a subcutaneous injection, it qualifies as a Part B benefit under the "incident to" rule. Medicare Part B generally covers 80% of the Medicare-approved amount after the Part B deductible is met, leaving a 20% coinsurance. For a $1,500 drug, that 20% amounts to roughly $300 per injection, or $600 per year, before any supplemental (Medigap) plan applies.

Patients enrolled in Medicare Advantage plans should check whether their plan uses the same Part B benefit structure or has a separate drug tier for physician-administered injectables.

Private Insurance Coverage for Prolia in South Dakota

Most commercial insurance plans sold in South Dakota cover denosumab, but coverage tier and cost-sharing vary widely across carriers.

Formulary tier placement. Prolia typically sits on Tier 4 or Tier 5 (specialty drug tier) in commercial formularies. A Tier 5 specialty copay can range from $100 to $400 per injection even with insurance, depending on whether the plan has a specialty cost-sharing accumulator or maximizer program.

Prior authorization requirements. Nearly every commercial insurer in South Dakota requires PA for Prolia. Common PA criteria include:

• Documented T-score of -2.5 or below at the spine or hip (meeting WHO criteria for osteoporosis) [3]
• Trial and failure or documented contraindication to a first-line bisphosphonate
• Prescribing physician documentation of fracture risk using a validated tool such as FRAX

Step therapy. Some plans require a 6-month trial of oral alendronate or risedronate before approving denosumab. South Dakota does not have a statewide step-therapy override law that specifically accelerates access for osteoporosis drugs, though the state's insurer-regulated override provisions allow a prescriber to request an exception based on medical necessity.

Out-of-pocket caps. The ACA out-of-pocket maximum for 2026 is $9,200 for individual coverage. Specialty drug costs count toward this cap, so patients with high-cost plans who use multiple specialty drugs may hit the cap mid-year.

The Amgen ASSIST360 Savings Card: How It Works in South Dakota

Amgen operates the ASSIST360 patient support program, which includes a copay card for commercially insured patients and a separate free drug program for uninsured or underinsured patients. [4]

Commercially insured patients. Eligible patients with commercial insurance (not Medicare, Medicaid, or any government-funded plan) may pay as little as $0 per injection through the Amgen copay card. The card offsets the patient's cost-sharing up to an annual program maximum. Enrollment is done online or by phone through ASSIST360.

Uninsured or underinsured patients. The Amgen Safety Net Foundation provides Prolia at no cost to patients who meet income eligibility criteria (generally at or below 500% of the federal poverty level) and have no adequate insurance coverage for the drug.

Program limits and restrictions. The copay card explicitly excludes patients whose primary coverage is Medicare Part B, Medicare Part D, Medicaid, or any other government-funded healthcare program. South Dakota patients on Medicare who are looking for cost relief cannot use the commercial copay card and must investigate other pathways (see below).

To enroll in ASSIST360, patients or their providers can call 1-800-272-9376 or visit the program page on Amgen's website. The enrollment process typically takes one business day.

Compounded Denosumab in South Dakota: Legal Status and Practical Considerations

South Dakota permits licensed 503A compounding pharmacies to prepare compounded denosumab for individual patients with a valid prescription from a licensed prescriber. A 503A pharmacy is a traditional compounding pharmacy that compounds drugs for specific individual patients, as defined under Section 503A of the Federal Food, Drug, and Cosmetic Act. [5]

What "503A" means for patients. A 503A pharmacy mixes or prepares a drug product based on a patient-specific prescription. Compounded denosumab from a 503A pharmacy is not the FDA-approved Prolia product, is not subject to the same manufacturing quality controls as brand-name Prolia, and has no equivalent efficacy or safety data from randomized trials. These are not minor caveats.

Cost. Compounded denosumab from 503A pharmacies may cost substantially less than brand-name Prolia, with some pharmacies offering formulations at dramatically reduced rates compared to the $1,500 brand-name price. Actual pricing varies by pharmacy and formulation. Patients should request an itemized quote and verify the pharmacy's state licensure with the South Dakota Board of Pharmacy before proceeding.

Regulatory context. The FDA has stated that compounding a drug that is "essentially a copy" of an approved product is not generally permissible under 503A unless there is a documented clinical difference (such as a different concentration or route justified by the patient's clinical need). Prescribers ordering compounded denosumab should document the specific clinical rationale. The American Association of Clinical Endocrinology (AACE) 2020 guidelines recommend FDA-approved agents as first-line therapy; deviation to compounded products requires a specific clinical justification. [6]

Quality considerations. A 2020 analysis in the Journal of Clinical Endocrinology and Metabolism noted that biologic compounding introduces potential concerns around protein stability, sterility, and immunogenicity that do not apply to the approved manufacturer product. [7] Patients and prescribers should weigh those risks against the cost benefit.

A practical decision framework for South Dakota patients:

1. Commercially insured, T-score < -2.5, bisphosphonate failure documented. Pursue PA through insurer plus Amgen ASSIST360 copay card. Expected out-of-pocket: $0 to $300 per injection.
2. Medicare Part B. Confirm benefit under Part B with your Medicare Advantage or supplemental plan. Expected out-of-pocket: $0 (Medigap) to $300 (20% coinsurance without Medigap).
3. South Dakota Medicaid. Submit PA with bisphosphonate contraindication documentation. If denied, consider oral bisphosphonate or referral to an academic bone health center for grant-funded access.
4. Uninsured, income <500% FPL. Apply to Amgen Safety Net Foundation.
5. Uninsured, income above threshold, or commercial insurance denial. Evaluate 503A compounded denosumab through a licensed South Dakota pharmacy with prescriber documentation of clinical rationale.

Telehealth Prescribing of Prolia in South Dakota

South Dakota permits telehealth prescribing of Prolia. A licensed prescriber (MD, DO, NP, or PA with prescribing authority) can evaluate a patient via synchronous video consultation, review existing DXA scan results and fracture history, and issue a Prolia prescription. The prescription can be filled at any licensed South Dakota pharmacy or through a mail-order pharmacy. [8]

Several national telehealth platforms serve South Dakota patients for bone health management. The standard workflow involves:

• Uploading a DXA scan report showing T-score and fracture risk
• A 20 to 30-minute video visit with a board-certified physician or licensed NP
• Prescription transmitted electronically to the patient's preferred pharmacy
• Injection administered by the patient, a home health nurse, or at a local clinic (infusion center or primary care office)

Patients who have never received Prolia should be aware that the injection requires proper subcutaneous technique. Many South Dakota primary care clinics will administer the injection for a modest office visit fee if the patient does not self-inject.

Hypocalcemia monitoring. The FDA label for Prolia requires that serum calcium levels be corrected before starting therapy and monitored during treatment. Patients with pre-existing hypocalcemia should not begin denosumab until the deficiency is corrected. Telehealth prescribers typically order a basic metabolic panel and 25-hydroxyvitamin D level before issuing the first prescription. [1]

Comparing Denosumab to Alternatives Available in South Dakota

South Dakota patients who cannot afford Prolia or whose insurance denies it have several evidence-based alternatives:

Alendronate (generic Fosamax). The most prescribed oral bisphosphonate in the US. 70 mg once weekly costs under $10 per month as a generic. AACE guidelines list alendronate as first-line for postmenopausal osteoporosis in patients without contraindications. [6] It does not require injection, but carries risks of esophageal irritation and, rarely, osteonecrosis of the jaw with long-term use.

Zoledronic acid (Reclast). An IV bisphosphonate given once yearly at 5 mg. The HORIZON-Key Fracture Trial (N=7,765) showed a 70% reduction in vertebral fracture risk vs placebo over 3 years (relative risk 0.30 to 95% CI 0.24, 0.38, P<0.001). [9] Medicare Part B covers IV zoledronic acid in the office setting, making it a cost-effective choice for Medicare patients who need an injectable option but cannot access Prolia cost-effectively.

Teriparatide (Forteo). A daily subcutaneous injection for 24 months. Indicated for patients with severe osteoporosis or fracture on antiresorptive therapy. List price exceeds $3,000 per month, making it less accessible than Prolia without strong assistance.

Romosozumab (Evenity). A monthly subcutaneous injection for 12 months that combines anabolic and antiresorptive effects. The ARCH trial (N=4,093) showed a 48% reduction in vertebral fracture risk vs alendronate over 24 months. [10] List price is comparable to Prolia; Amgen also markets romosozumab and offers a similar savings program.

The Endocrine Society's 2019 clinical practice guideline on osteoporosis in postmenopausal women states: "We recommend treatment with pharmacological therapy in postmenopausal women at high risk for fracture," and notes that the choice between agents should account for individual fracture risk, comorbidities, cost, and patient preference. [11]

What Happens If You Stop Denosumab

This question carries real clinical weight and affects cost planning. Denosumab suppresses bone resorption only as long as the drug is active. When patients stop therapy, RANKL pathways reactivate rapidly, and BMD returns to pre-treatment levels within 12 to 24 months. Multiple case series have documented rebound vertebral fractures following denosumab discontinuation, some occurring within six months of a missed dose. [12]

The practical implication: patients who start Prolia should plan for long-term or indefinite use, or have a clearly defined transition strategy to an oral bisphosphonate (typically alendronate for at least 12 months after stopping denosumab). The 2023 AACE/ACE osteoporosis guidelines explicitly recommend a sequential antiresorptive after denosumab discontinuation to prevent rebound bone loss. [6]

From a cost standpoint, this means the $3,000 annual expense is not a time-limited course. Patients and prescribers should build that into the access plan from day one, ensuring the insurance, savings program, or compounding pathway chosen can sustain treatment for multiple years.

South Dakota-Specific Resources for Prolia Access

Several resources are particularly relevant to South Dakota patients seeking to reduce Prolia costs:

• South Dakota Department of Social Services (Medicaid PA requests). Available at dss.sd.gov. Providers submit PA forms for nonpreferred drugs here.
• Amgen ASSIST360. 1-800-272-9376. Covers copay assistance and the Safety Net Foundation free drug program.
• South Dakota Board of Pharmacy (503A pharmacy verification). sdpharmd.sd.gov. Verify that a compounding pharmacy is licensed in South Dakota before filling a compounded denosumab prescription.
• National Osteoporosis Foundation / Bone Health and Osteoporosis Foundation (BHOF). Offers a patient resource guide with a state-by-state assistance directory.
• Medicare Extra Help (Low Income Subsidy). For Part D drugs; denosumab under Part B is a separate benefit, but Medicare Extra Help may reduce Part B coinsurance for dual-eligible patients.
• GoodRx and NeedyMeds. Cash-discount programs at retail pharmacies. Because Prolia has no generic equivalent as of mid-2025, GoodRx discounts on brand-name Prolia are minimal (typically saving under $100 from the $1,500 list price), but checking remains worthwhile.